{"id":3748,"date":"2021-04-08T11:39:35","date_gmt":"2021-04-08T10:39:35","guid":{"rendered":"http:\/\/med.st-andrews.ac.uk\/tbtrials\/?p=3748"},"modified":"2023-05-01T17:53:46","modified_gmt":"2023-05-01T16:53:46","slug":"stand-shortening-treatment-by-advancing-novel-drugs-trial","status":"publish","type":"post","link":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/2021\/04\/08\/stand-shortening-treatment-by-advancing-novel-drugs-trial\/","title":{"rendered":"STAND (Shortening Treatment by Advancing Novel Drugs) Trial"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.20.2″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″ admin_label=”STAND”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title _builder_version=”4.20.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_post_title][et_pb_text _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”10px|||||” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]The Infection and Global Health Division are committed to finding new and better treatment for tuberculosis (TB) through high quality clinical trials.\u00a0 Our work continues to test regimens including the novel drug pretomanid, developed by the TB Alliance<\/a>.\u00a0 We participated in their recent global STAND (Shortening Treatment by Advancing Novel Drugs) trial that included sites from across Africa, the Far East and Ukraine, and treated participants with pulmonary drug-susceptible TB (DS-TB).\u00a0 We compared a regimen consisting of pyrazinamide, moxifloxacin and pretomanid for four months with the standard WHO DS-TB\u00a0 regimen for six months.\u00a0\u00a0\u00a0 The paper has now been published in the International Journal of Tuberculosis and Lung Diseases: https:\/\/www.ingentaconnect.com\/contentone\/iuatld\/ijtld\/2021\/00000025\/00000004\/art00009<\/a>.<\/p>\n

The same team are continuing to evaluate novel pretomanid regimens through the SimpliciTB<\/a> \u00a0(Simplified Short Treatment for Tuberculosis) trial.
\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

The Infection and Global Health Division are committed to finding new and better treatment for tuberculosis (TB) through high quality clinical trials.\u00a0 Our work continues to test regimens including the novel drug pretomanid, developed by the TB Alliance.\u00a0 We participated in their recent global STAND (Shortening Treatment by Advancing Novel Drugs) trial that included sites […]<\/p>\n","protected":false},"author":159,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"

The Infection and Global Health Division are committed to finding new and better treatment for tuberculosis (TB) through high quality clinical trials.\u00a0 Our work continues to test regimens including the novel drug pretomanid, developed by the TB Alliance<\/a>.\u00a0 We participated in their recent global STAND (Shortening Treatment by Advancing Novel Drugs) trial that included sites from across Africa, the Far East and Ukraine, and treated participants with pulmonary drug-susceptible TB (DS-TB).\u00a0 We compared a regimen consisting of pyrazinamide, moxifloxacin and pretomanid for four months with the standard WHO DS-TB\u00a0 regimen for six months.\u00a0\u00a0\u00a0 The paper has now been published in the International Journal of Tuberculosis and Lung Diseases: https:\/\/www.ingentaconnect.com\/contentone\/iuatld\/ijtld\/2021\/00000025\/00000004\/art00009<\/a>.<\/p>

The same team are continuing to evaluate novel pretomanid regimens through the SimpliciTB<\/a> \u00a0(Simplified Short Treatment for Tuberculosis) trial.<\/p>","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3748","post","type-post","status-publish","format-standard","hentry","category-uncategorised"],"publishpress_future_action":{"enabled":false,"date":"2026-06-03 00:41:43","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/posts\/3748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/users\/159"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/comments?post=3748"}],"version-history":[{"count":0,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/posts\/3748\/revisions"}],"wp:attachment":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/media?parent=3748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/categories?post=3748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/tags?post=3748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}